Insights

An FDA advisory committee recommends approval of Eli Lilly’s Alzheimer’s drug, the Biden administration proposes banning medical debt from credit reports, and Elevance becomes the second insurer to w... read more

Portland, OR-based health systems OHSU and Legacy sign a definitive merger agreement, Dollar General ends its mobile health clinic pilot, and a House subcommittee focuses on the need for 340B transpa... read more

Ozempic trial shows the drug slows kidney disease progression, a blood-based colorectal cancer test is endorsed for FDA approval, and nursing home trade groups sue over the new staffing mandate. read more

Telehealth company Hims & Hers unveils $199 weight-loss shots, CMS launches an emergency care complaint portal for patients, and the Senate Finance Committee signals interest in Medicare physician pa... read more

Hospitals and health systems that participate in the federal 340B Drug Pricing Program are currently facing challenges on multiple fronts, including manufacturer restrictions and program audits, lega... read more

Margins are tight everywhere in healthcare, but a hospital’s pharmacy department has a strong capacity to bring value — especially if that organization has an established chief pharmacy officer as pa... read more

Amid a macroenvironment of inflation and rising healthcare costs, healthcare leaders should carefully assess these microeconomic trends as part of their hospital-based laboratory decision-making thro... read more

While the supply chain may feel complex, the good news is that there are still methods — like Drug Shortage Stewardship — that can be implemented to mitigate drug shortages. read more

Drug shortages and their management have become a major focus of pharmacy staff within hospitals and health systems, which is why maintaining an institution-specific drug shortage list may be critica... read more

Stacy Lauderdale, Vizient AVP, and John Shoen, senior clinical manager, discuss two potential approaches to preventing RSV in pediatrics expected to receive FDA decisions this year. read more